Healthcare
Syros Pharmaceuticals, Inc.(SYRS)
Live Price
Offline$0.0001
-75.00% today
1Y Change
-99.63%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- โ
- Revenue Growth
- -33.2%
- EPS Growth
- +22.4%
- Dividend Yield
- 0.0%
Coverage: 240 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Syros Pharmaceuticals, Inc. (SYRS) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 99.6% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -33.2%, EPS growth of +22.4%, a dividend yield of 0.0%. What stands out right now is revenue -33.2%, EPS +22.4%, free cash flow +11.5% with operating margin -1298.2% and ROIC -91.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SYRS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-33.2% vs +7.6% peer median
Operating Margin
Below sector median
-1298.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -33.2% and EPS is at +22.4%, with operating margin around -1298.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +8.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 25, 2026 | โ | +75.0% | +0.0% | +0.0% |
2025 Oct 29, 2025 | โ | +0.0% | +25.0% | +25.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYRS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SYRS Max Drawdown
-99.67%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SYRS and SPY.
Company Overview
Syros Pharmaceuticals, Inc.
Other OTC
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
- Leadership
- James E. Bradner
- IPO Date
- Jun 30, 2016
- Employees
- 68
- Street Address
- 35 CambridgePark Drive
- Mailing
- Cambridge, MA, 02140
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 744 1340
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.5
- Price/Sales
- 0.0
- Price/Book
- 0.0
Growth
- Revenue
- -33.2%
- EPS
- +22.4%
- Free Cash Flow
- +11.5%
Profitability
- Gross Margin
- 77.3%
- Operating Margin
- -1298.2%
- Net Margin
- -1656.3%
- ROE
- -227.9%
- ROIC
- -91.8%
Balance Sheet
- Debt/Equity
- 3.73
- Current Ratio
- 3.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.